Skip to main content

Table 1 Baseline characteristics of patients (intention-to-treat population, N = 34)

From: A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma

Characteristic

Age - year

 

 Median

54

 Range

27-73

GenderN (%)

 

 Male

18 (52.9)

 Female

16 (47.1)

Duration of disease - year

 

(from initial diagnosis to study enrollment)

 

 Median (Mean)

4.4 (6.0)

 Range

0.5-22.0

Primary siteN (%)

 

 Salivary gland

13 (38.2)

 Paranasal sinus

8 (23.5)

 Oral cavity/oropharynx

6 (17.6)

 Nasal cavity/nasopharynx

2 (5.9)

 Larynx

2 (5.9)

 Lung

1 (2.9)

 Bartholin gland

1 (2.9)

 Unknown

1 (2.9)

Site of metastasisN (%)

 

 Lung

32 (94.1)

 Bone

8 (23.5)

 Non-regional lymph nodes

5 (14.7)

 Liver

3 (8.8)

 Soft tissue

3 (8.8)

 Pleura

2 (5.9)

 Kidney

2 (5.9)

 Adrenal gland

1 (2.9)

 Peritoneum

1 (2.9)

 Brain

1 (2.9)

 Spleen

1 (2.9)

 Eyeball

1 (2.9)